MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Published:2022-01 Issue: Volume:29 Page:S145-S154
ISSN:1076-6332
Container-title:Academic Radiology
language:en
Short-container-title:Academic Radiology

Author:

Choudhery Sadia,Gomez-Cardona Daniel,Favazza Christopher P,Hoskin Tanya L,Haddad Tufia C,Goetz Matthew P,Boughey Judy C

Funder

National Cancer Institute

Eli Lilly and Company

National Institutes of Health

Pfizer

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging

Reference38 articles.

1. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer;Holmes;Ann Surg Oncol,2015

2. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy;Mougalian;JAMA Oncol,2016

3. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007:CD005002. http://doi.org/10.1002/14651858.CD005002.pub2

4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

5. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy;Symmans;J Clin Oncol,2007

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-invasive prediction of axillary lymph node dissection exemption in breast cancer patients post-neoadjuvant therapy: A radiomics and deep learning analysis on longitudinal DCE-MRI data;The Breast;2024-10

2. Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy;Radiology;2024-09-01

3. Predicting response of hepatoblastoma primary lesions to neoadjuvant chemotherapy through contrast-enhanced computed tomography radiomics;Journal of Cancer Research and Clinical Oncology;2024-04-30

4. Multiparametric MR-based radiomics fusion combined with quantitative stratified ADC-defined tumor habitats for differentiating TNBC versus non-TNBC;Physics in Medicine & Biology;2024-02-28

5. Radiomic model based on magnetic resonance imaging for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer patients;Frontiers in Oncology;2024-01-31